{"id":19995,"date":"2023-04-27T06:06:01","date_gmt":"2023-04-27T04:06:01","guid":{"rendered":"https:\/\/d36deud6t4mnhi.cloudfront.net\/patients\/lay-language-summaries\/"},"modified":"2025-08-08T11:20:42","modified_gmt":"2025-08-08T09:20:42","slug":"resumes-vulgarises-de-nos-essais-cliniques","status":"publish","type":"page","link":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/patients\/resumes-vulgarises-de-nos-essais-cliniques\/","title":{"rendered":"R\u00e9sum\u00e9s vulgaris\u00e9s de nos essais cliniques"},"content":{"rendered":"    <section class=\"sub-page-banner bg-img\" style=\"background-image:url(https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2025\/08\/08093811\/Science-Lay-Summaries.jpg)\">\n        <div class=\"container content-sec\" role=\"main\" id=\"main\">\n            <nav aria-label=\"breadcrumb\">\n            <ol class=\"breadcrumb\">\n                <li class=\"breadcrumb-item\"><a href=\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/\">Accueil<\/a><\/li><li class=\"breadcrumb-item active\"><a href=\"#\" aria-current=\"page\">Science &#8211; R\u00e9sum\u00e9s vulgaris\u00e9s de nos essais cliniques<\/a><\/li><\/ol>\n            <\/nav>            <h1 class=\"visible\">R\u00e9sum\u00e9s vulgaris\u00e9s de nos essais cliniques<\/h1>\n            <p class=\"visible\"><\/p>\n        <\/div>\n    <\/section>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:75%\">    <section class=\"title-text \">\n        <div class=\"container\">\n            <div class=\"title-text-inner\" style=\"background-color:#EDEBE4;\">\n\n                <!-- If heading is enabled then it's visible -->\n                <div class=\"text-head-dash hidden\">\n                    <h3 class=\"heading-three\">\n                                            <\/h3>\n                <\/div>\n               \n                <!-- If description is enabled then it's visible -->\n                <div class=\"text-parbase visible\">\n                    <p>Ipsen s&rsquo;engage \u00e0 fournir des r\u00e9sum\u00e9s vulgaris\u00e9s de recherche en langage clair et simple pour tous ses essais cliniques interventionnels qui ont d\u00e9but\u00e9 \u00e0 partir de janvier 2022 ou qui ont d\u00e9but\u00e9 avant janvier 2022 et dont la date de fin est post\u00e9rieure \u00e0 janvier 2023. Ces r\u00e9sum\u00e9s visent \u00e0 rendre les informations sur les \u00e9tudes cliniques accessibles \u00e0 tous. Ils sont g\u00e9n\u00e9ralement publi\u00e9s dans l&rsquo;ann\u00e9e qui suit la fin de l&rsquo;essai ou peu apr\u00e8s l&rsquo;octroi de l&rsquo;autorisation de mise sur le march\u00e9. Des traductions dans la langue locale peuvent \u00eatre disponibles sur demande. Contactez <a href=\"mailto:clinical.trials@ipsen.com\">clinical.trials@ipsen.com <\/a>pour plus d\u2019informations.<\/p>\n<p>Sur cette page, vous trouverez des r\u00e9sum\u00e9s d&rsquo;essais cliniques qu&rsquo;Ipsen a sponsoris\u00e9s et d&rsquo;essais cliniques qui ont \u00e9t\u00e9 acquis par Ipsen. Vous pouvez utiliser la barre de recherche pour trouver des r\u00e9sum\u00e9s par mot-cl\u00e9 et la liste d\u00e9roulante pour trouver des r\u00e9sum\u00e9s par condition(s).<\/p>\n                <\/div>\n\n                <!-- If button is enabled then it's visible -->\n                \n            <\/div>\n        <\/div>\n    <\/section>\n\n\n\n<!--Alert Card Layout Start Here-->\n<section class=\"alertcard-section\">\n      <div class=\"container\">\n        <!--Alert Box HTML Start Here-->\n        <div class=\"alert-box warning-box\">\n                    <div class=\"info-icon\">\n              <span class=\"info-circle\"><img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/alert-warning-icon.png\" alt=\"Ic\u00f4ne d'alerte\"\/><\/i>\n            <\/div>\n                    <div class=\"info-contents\">\n            <h4 class=\"info-head heading-four heading-four\"><\/h4>\n            <p class=\"info-sub-head-para hidden heading-para\"><\/p>\n            <div class=\"alert-content visible\"><p>Les r\u00e9sum\u00e9s fournis ici servent \u00e0 des fins d&rsquo;information et ne sont pas destin\u00e9s \u00e0 un usage promotionnel. Ils ne constituent en aucun cas une forme d&rsquo;approbation, de recommandation ou de sollicitation. En revanche, ils r\u00e9pondent aux exigences r\u00e9glementaires et refl\u00e8tent notre engagement de transparence en mati\u00e8re d&rsquo;essais cliniques.<\/p>\n<\/div>\n          <\/div>\n        <\/div>\n        <!--Alert Box HTML Start Here-->\n      <\/div>\n    <\/section>\n<!--Alert Card Layout End Here-->\n\n\n<section class=\"media-filter laylanguage-content-div\">\n    <div class=\"container media-filter-inner\">\n                        <h3 class=\"media-filter-title charcoal-grey heading-three\">\n                                    <\/h3>\n                <div class=\"media-filter-main\">\n            <div class=\"row\">\n                <div class=\"column-1 col-xl-9 col-md-8 col-sm-12\">\n                    <!-- media drop down -->\n                                                <div class=\"media-drop-down\">\n                                <p class=\"media-drop-heading\">Filtre<\/p>\n                                <div class=\"media-dropdown-items\">\n                                    <div class=\"row\">\n                                                                                    <div class=\"column-1 col-lg-4 col-md-4 col-sm-12\">\n                                                <div class=\"laylanguage-filter\">\n                                                    <p>Condition<\/p>\n                                                    <div class=\"mutltiselect-dropdown laylanguage-cat-dropdown\">\n                                                        <select name=\"langOpt[]\" multiple id=\"laylanguageOpt\">\n                                                                                                                    <\/select>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                                                                                                            <div class=\"column-2 col-lg-4 col-md-4 col-sm-12\">\n                                                <div class=\"period-filter\">\n                                                    <p>P\u00e9riode<\/p>\n                                                    <div class=\"mutltiselect-dropdown laylanguageyear-dropdown\">\n                                                        <select name=\"langOpt[]\" multiple id=\"laylanguageperiodOpt\">\n                                                                                                                            <option value=\"2025\">2025                                                                                                                            <option value=\"2024\">2024                                                                                                                            <option value=\"2023\">2023                                                                                                                            <option value=\"2022\">2022                                                                                                                            <option value=\"2021\">2021                                                                                                                            <option value=\"2020\">2020                                                                                                                            <option value=\"2019\">2019                                                                                                                            <option value=\"2018\">2018                                                                                                                            <option value=\"2017\">2017                                                                                                                            <option value=\"2016\">2016                                                                                                                    <\/select>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                                                                                                            <div class=\"column-3 col-lg-4 col-md-4 \">\n                                                <div class=\"filterby-filter\">\n                                                    <p>Filtrer par<\/p>\n                                                    <div class=\"input-filter\">\n                                                        <input type=\"search\" name=\"filter-by\" id=\"laylangauage-filter-by\"\n                                                            placeholder=\"Type a keyword\">\n                                                    <\/div>\n                                                    <div class=\"filter-by-dropdown\">\n                                                        <p class=\"recent\">recherche r\u00e9cente<\/p>\n                                                                                                                <ul class=\"filter-by-list\">\n                                                                                                                    <\/ul>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                                                            <\/div>\n                                    <div class=\"reset-btn-div\">\n                                        <a href=\"#\" class=\"reset-btn\">R\u00e9initialiser<\/a>\n                                    <\/div>\n                                <\/div>\n                            <\/div>\n                                        <!-- sorting section -->\n                    <div class=\"sorting-sec\">\n                        <div class=\"row\">\n                                                    <div class=\"column-1 col-xl-6 col-lg-6 col-sm-12\">\n                                <div class=\"no-of-item-sec\">\n                                    <p> Afficher: <span id=\"start-value\">1<\/span> &#8211;<span id=\"no-of-search\"> 05 <\/span> de <span id=\"total-count\">12<\/span>\n                                    Conditions<\/p>\n                                <\/div>\n                            <\/div>\n                                                    <div class=\"column-2 col-xl-5 col-lg-6 col-sm-12\">\n                                                            <div class=\"sort-input\">\n                                    <div class=\"sort-input-inner\">\n                                        <label for=\"sorting-input\">Afficher<\/label>\n                                        <select name=\"order\" aria-label=\"5\" id=\"show-laylangauage-list\" tabindex=\"0\">\n                                            <option value=\"05\">05<\/option>\n                                            <option value=\"10\">10<\/option>\n                                            <option value=\"20\">20<\/option>\n                                            <option value=\"30\">30<\/option>\n                                            <option value=\"40\">40<\/option>\n                                            <option value=\"50\">50<\/option>\n                                        <\/select>\n                                    <\/div>\n                                <\/div>\n                                                                                                <div class=\"sort-input-ascending\">\n                                    <div class=\"sort-input-ascending-inner\">\n                                        <label for=\"sorting-input-ascend\">Trier par<\/label>\n                                        <select name=\"sorting-input-ascend\" id=\"show-laylangauage-list-as\" aria-label=\"Ascending\" tabindex=\"0\">\n                                            <option value=\"DESC\" aria-label=\"Descendant\">Descendant<\/option>\n                                            <option value=\"ASC\" aria-label=\"Ascendant\">Ascendant<\/option>\n                                        <\/select>\n                                    <\/div>\n                                <\/div>\n                                                            <\/div>\n                        <\/div>\n                    <\/div>\n                        <!-- Story Listing start here -->\n                        <div class=\"story-div laylanguage-card\" id=\"laylanguage-card\">\n                                                                    <div class=\"row story-row\">\n                                            <div class=\"column-1 col-lg-2 col-md-2 col-sm-12\">\n                                                                                                        <div class=\"story-img\">\n                                                                                                                            <a href=\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/lay-language\/une-etude-pour-connaitre-les-effets-et-la-securite-du-tazemetostat-chez-les-personnes-atteintes-dune-tumeur-a-interacteur-1-ini-1-negative-ou-dun-sarcome-synovial-en-rechute-ou-refractaire\/\">\n                                                                    <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/defaultImg.png\" alt=\"Une \u00e9tude pour conna\u00eetre les effets et la s\u00e9curit\u00e9 du taz\u00e9m\u00e9tostat chez les personnes atteintes d'une tumeur \u00e0 interacteur-1 (INI-1) n\u00e9gative ou d'un sarcome synovial en rechute ou r\u00e9fractaire\" title=\"Une \u00e9tude pour conna\u00eetre les effets et la s\u00e9curit\u00e9 du taz\u00e9m\u00e9tostat chez les personnes atteintes d'une tumeur \u00e0 interacteur-1 (INI-1) n\u00e9gative ou d'un sarcome synovial en rechute ou r\u00e9fractaire\" >\n                                                                <\/a>\n                                                                                                                    <\/div>\n                                                                                            <\/div>\n                                            <div class=\"column-2 col-lg-10 col-md-10 col-sm-12\">\n                                                <div class=\"story-post\">\n                                                    <div class=\"story-time-div\">\n                                                        <div class=\"story-info-sec\">\n                                                            <button class=\"btn tag-btn\" style=\"background-color:#017bbc\">\n                                                                Sarcome des tissus mous                                                            <\/button>\n                                                            <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/doc.svg\"\n                                                                class=\"radio-img desk-span\" alt=\"Ic\u00f4ne de document\" title=\"Ic\u00f4ne de document\" srcset=\"\" width=\"auto\">\n                                                            <span class=\"desk-span\">&nbsp;&#8211;&nbsp;\n                                                                <span class=\"story-date\">26 janvier 2025                                                                    <!-- <span class=\"story-read-time\">1 \u00a0mn de lecture<\/span> -->\n                                                                <\/span>\n                                                                <p class=\"mob-span\">\n                                                                    <span class=\"story-date\">26 janvier 2025<\/span>\n                                                                    <!-- <span class=\"story-read-time\"><\/span> -->\n                                                                <\/p>\n                                                        <\/div>\n                                                                                                                <div class=\"download-icon\">\n                                                            <a href=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2025\/02\/24092636\/ezh202-lay-results-summary-FR.pdf\" target=\"_blank\">\n                                                                <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/download.svg\"\n                                                                alt=\"T\u00e9l\u00e9charger\" title=\"T\u00e9l\u00e9charger\" target=\"_blank\">\n                                                            <\/a>\n                                                        <\/div>\n                                                                                                                <div class=\"story-share-sec visible\">\n                                                            <div class=\"share\" data-title=\" Une \u00e9tude pour conna\u00eetre les effets et la s\u00e9curit\u00e9 du taz\u00e9m\u00e9tostat chez les personnes atteintes d&rsquo;une tumeur \u00e0 interacteur-1 (INI-1) n\u00e9gative ou d&rsquo;un sarcome synovial en rechute ou r\u00e9fractaire\">\n                                                                <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/share-icon.svg\"\n                                                                alt=\"Partager sur les r\u00e9seaux sociaux\" title=\"Partager sur les r\u00e9seaux sociaux\" \/>\n                                                            <\/div>\n                                                            <div class=\"share-tray hidden\">\n                                                                                                                                <a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https:\/\/d14saept1n0koz.cloudfront.net\/fr\/lay-language\/une-etude-pour-connaitre-les-effets-et-la-securite-du-tazemetostat-chez-les-personnes-atteintes-dune-tumeur-a-interacteur-1-ini-1-negative-ou-dun-sarcome-synovial-en-rechute-ou-refractaire\/&#038;title=Une \u00e9tude pour conna\u00eetre les effets et la s\u00e9curit\u00e9 du taz\u00e9m\u00e9tostat chez les personnes atteintes d'une tumeur \u00e0 interacteur-1 (INI-1) n\u00e9gative ou d'un sarcome synovial en rechute ou r\u00e9fractaire&#038;media=\">\n                                                                    <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/LinkedIn.svg\" alt=\"Partager sur LinkedIn\" title=\"Partager sur LinkedIn\" \/>LinkedIn\n                                                                <\/a>\n                                                                                                                                <!--<a href=\"\">\n                                                                    <img decoding=\"async\" src=\"\" alt=\"\" title=\"\" \/>Twitter\n                                                                <\/a>-->\n                                                                                                                                <a href=\"https:\/\/www.facebook.com\/sharer.php?u=https:\/\/d14saept1n0koz.cloudfront.net\/fr\/lay-language\/une-etude-pour-connaitre-les-effets-et-la-securite-du-tazemetostat-chez-les-personnes-atteintes-dune-tumeur-a-interacteur-1-ini-1-negative-ou-dun-sarcome-synovial-en-rechute-ou-refractaire\/&#038;p=Une \u00e9tude pour conna\u00eetre les effets et la s\u00e9curit\u00e9 du taz\u00e9m\u00e9tostat chez les personnes atteintes d'une tumeur \u00e0 interacteur-1 (INI-1) n\u00e9gative ou d'un sarcome synovial en rechute ou r\u00e9fractaire\">\n                                                                    <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/Facebook.svg\" alt=\"Partager sur Facebook\" title=\"Partager sur Facebook\" \/>Facebook\n                                                                <\/a>\n                                                                                                                            <\/div>\n                                                        <\/div>\n                                                                                                            <\/div>\n                                                    <div class=\"story-post-content\">\n                                                        <a href=\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/lay-language\/une-etude-pour-connaitre-les-effets-et-la-securite-du-tazemetostat-chez-les-personnes-atteintes-dune-tumeur-a-interacteur-1-ini-1-negative-ou-dun-sarcome-synovial-en-rechute-ou-refractaire\/\">\n                                                            <p class=\"blue-txt\">Une \u00e9tude pour conna\u00eetre les effets et la s\u00e9curit\u00e9 du taz\u00e9m\u00e9tostat chez les personnes atteintes d&rsquo;une tumeur \u00e0 interacteur-1 (INI-1) n\u00e9gative ou d&rsquo;un sarcome synovial en rechute ou r\u00e9fractaire<\/p>\n                                                        <\/a>\n                                                        <p class=\"second-post-para\">Tazverik<\/p>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                        <\/div>\n                                        <br>\n                                                                    <div class=\"row story-row\">\n                                            <div class=\"column-1 col-lg-2 col-md-2 col-sm-12\">\n                                                                                                        <div class=\"story-img\">\n                                                                                                                            <a href=\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/\">\n                                                                    <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/defaultImg.png\" alt=\"Une \u00e9tude comparant les effets de l'irinot\u00e9can liposomal au traitement standard chez les personnes dont le cancer du poumon s'est aggrav\u00e9 apr\u00e8s le traitement initial.\" title=\"Une \u00e9tude comparant les effets de l'irinot\u00e9can liposomal au traitement standard chez les personnes dont le cancer du poumon s'est aggrav\u00e9 apr\u00e8s le traitement initial.\" >\n                                                                <\/a>\n                                                                                                                    <\/div>\n                                                                                            <\/div>\n                                            <div class=\"column-2 col-lg-10 col-md-10 col-sm-12\">\n                                                <div class=\"story-post\">\n                                                    <div class=\"story-time-div\">\n                                                        <div class=\"story-info-sec\">\n                                                            <button class=\"btn tag-btn\" style=\"background-color:#0668e0\">\n                                                                Cancer du poumon                                                            <\/button>\n                                                            <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/doc.svg\"\n                                                                class=\"radio-img desk-span\" alt=\"Ic\u00f4ne de document\" title=\"Ic\u00f4ne de document\" srcset=\"\" width=\"auto\">\n                                                            <span class=\"desk-span\">&nbsp;&#8211;&nbsp;\n                                                                <span class=\"story-date\">01 octobre 2024                                                                    <!-- <span class=\"story-read-time\">1 \u00a0mn de lecture<\/span> -->\n                                                                <\/span>\n                                                                <p class=\"mob-span\">\n                                                                    <span class=\"story-date\">01 octobre 2024<\/span>\n                                                                    <!-- <span class=\"story-read-time\"><\/span> -->\n                                                                <\/p>\n                                                        <\/div>\n                                                                                                                <div class=\"download-icon\">\n                                                            <a href=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/10\/24092632\/MM-398-01-03-04_PLS_Final-Draft_Clean_22-Oct-2024_FR-FR.pdf\" target=\"_blank\">\n                                                                <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/download.svg\"\n                                                                alt=\"T\u00e9l\u00e9charger\" title=\"T\u00e9l\u00e9charger\" target=\"_blank\">\n                                                            <\/a>\n                                                        <\/div>\n                                                                                                                <div class=\"story-share-sec visible\">\n                                                            <div class=\"share\" data-title=\" Une \u00e9tude comparant les effets de l&rsquo;irinot\u00e9can liposomal au traitement standard chez les personnes dont le cancer du poumon s&rsquo;est aggrav\u00e9 apr\u00e8s le traitement initial.\">\n                                                                <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/share-icon.svg\"\n                                                                alt=\"Partager sur les r\u00e9seaux sociaux\" title=\"Partager sur les r\u00e9seaux sociaux\" \/>\n                                                            <\/div>\n                                                            <div class=\"share-tray hidden\">\n                                                                                                                                <a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https:\/\/d14saept1n0koz.cloudfront.net\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/&#038;title=Une \u00e9tude comparant les effets de l'irinot\u00e9can liposomal au traitement standard chez les personnes dont le cancer du poumon s'est aggrav\u00e9 apr\u00e8s le traitement initial.&#038;media=\">\n                                                                    <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/LinkedIn.svg\" alt=\"Partager sur LinkedIn\" title=\"Partager sur LinkedIn\" \/>LinkedIn\n                                                                <\/a>\n                                                                                                                                <!--<a href=\"\">\n                                                                    <img decoding=\"async\" src=\"\" alt=\"\" title=\"\" \/>Twitter\n                                                                <\/a>-->\n                                                                                                                                <a href=\"https:\/\/www.facebook.com\/sharer.php?u=https:\/\/d14saept1n0koz.cloudfront.net\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/&#038;p=Une \u00e9tude comparant les effets de l'irinot\u00e9can liposomal au traitement standard chez les personnes dont le cancer du poumon s'est aggrav\u00e9 apr\u00e8s le traitement initial.\">\n                                                                    <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/Facebook.svg\" alt=\"Partager sur Facebook\" title=\"Partager sur Facebook\" \/>Facebook\n                                                                <\/a>\n                                                                                                                            <\/div>\n                                                        <\/div>\n                                                                                                            <\/div>\n                                                    <div class=\"story-post-content\">\n                                                        <a href=\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/\">\n                                                            <p class=\"blue-txt\">Une \u00e9tude comparant les effets de l&rsquo;irinot\u00e9can liposomal au traitement standard chez les personnes dont le cancer du poumon s&rsquo;est aggrav\u00e9 apr\u00e8s le traitement initial.<\/p>\n                                                        <\/a>\n                                                        <p class=\"second-post-para\">Onivyde<\/p>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                        <\/div>\n                                        <br>\n                                                                    <div class=\"row story-row\">\n                                            <div class=\"column-1 col-lg-2 col-md-2 col-sm-12\">\n                                                                                                        <div class=\"story-img\">\n                                                                                                                            <a href=\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/\">\n                                                                    <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2025\/01\/24092629\/Image1-2.png\" alt=\"Une \u00e9tude sur le cabozantinib chez des personnes atteintes d'un cancer du rein \u00e0 un stade avanc\u00e9 qui n'a pas pu \u00eatre trait\u00e9 par chirurgie et dont l'\u00e9tat s'est aggrav\u00e9 apr\u00e8s le traitement initial\" title=\"Une \u00e9tude sur le cabozantinib chez des personnes atteintes d'un cancer du rein \u00e0 un stade avanc\u00e9 qui n'a pas pu \u00eatre trait\u00e9 par chirurgie et dont l'\u00e9tat s'est aggrav\u00e9 apr\u00e8s le traitement initial\" >\n                                                                <\/a>\n                                                                                                                    <\/div>\n                                                                                            <\/div>\n                                            <div class=\"column-2 col-lg-10 col-md-10 col-sm-12\">\n                                                <div class=\"story-post\">\n                                                    <div class=\"story-time-div\">\n                                                        <div class=\"story-info-sec\">\n                                                            <button class=\"btn tag-btn\" style=\"background-color:#167bba\">\n                                                                Carcinome \u00e0 cellules r\u00e9nales m\u00e9tastatique                                                            <\/button>\n                                                            <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/doc.svg\"\n                                                                class=\"radio-img desk-span\" alt=\"Ic\u00f4ne de document\" title=\"Ic\u00f4ne de document\" srcset=\"\" width=\"auto\">\n                                                            <span class=\"desk-span\">&nbsp;&#8211;&nbsp;\n                                                                <span class=\"story-date\">01 septembre 2024                                                                    <!-- <span class=\"story-read-time\">1 \u00a0mn de lecture<\/span> -->\n                                                                <\/span>\n                                                                <p class=\"mob-span\">\n                                                                    <span class=\"story-date\">01 septembre 2024<\/span>\n                                                                    <!-- <span class=\"story-read-time\"><\/span> -->\n                                                                <\/p>\n                                                        <\/div>\n                                                                                                                <div class=\"download-icon\">\n                                                            <a href=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/09\/24092631\/F-FR-60000-023_PLS_Final-Draft_25-Sep-2024_Clean_FR-FR.pdf\" target=\"_blank\">\n                                                                <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/download.svg\"\n                                                                alt=\"T\u00e9l\u00e9charger\" title=\"T\u00e9l\u00e9charger\" target=\"_blank\">\n                                                            <\/a>\n                                                        <\/div>\n                                                                                                                <div class=\"story-share-sec visible\">\n                                                            <div class=\"share\" data-title=\" Une \u00e9tude sur le cabozantinib chez des personnes atteintes d&rsquo;un cancer du rein \u00e0 un stade avanc\u00e9 qui n&rsquo;a pas pu \u00eatre trait\u00e9 par chirurgie et dont l&rsquo;\u00e9tat s&rsquo;est aggrav\u00e9 apr\u00e8s le traitement initial\">\n                                                                <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/share-icon.svg\"\n                                                                alt=\"Partager sur les r\u00e9seaux sociaux\" title=\"Partager sur les r\u00e9seaux sociaux\" \/>\n                                                            <\/div>\n                                                            <div class=\"share-tray hidden\">\n                                                                                                                                <a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https:\/\/d14saept1n0koz.cloudfront.net\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/&#038;title=Une \u00e9tude sur le cabozantinib chez des personnes atteintes d'un cancer du rein \u00e0 un stade avanc\u00e9 qui n'a pas pu \u00eatre trait\u00e9 par chirurgie et dont l'\u00e9tat s'est aggrav\u00e9 apr\u00e8s le traitement initial&#038;media=https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2025\/01\/24092629\/Image1-2.png\">\n                                                                    <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/LinkedIn.svg\" alt=\"Partager sur LinkedIn\" title=\"Partager sur LinkedIn\" \/>LinkedIn\n                                                                <\/a>\n                                                                                                                                <!--<a href=\"\">\n                                                                    <img decoding=\"async\" src=\"\" alt=\"\" title=\"\" \/>Twitter\n                                                                <\/a>-->\n                                                                                                                                <a href=\"https:\/\/www.facebook.com\/sharer.php?u=https:\/\/d14saept1n0koz.cloudfront.net\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/&#038;p=Une \u00e9tude sur le cabozantinib chez des personnes atteintes d'un cancer du rein \u00e0 un stade avanc\u00e9 qui n'a pas pu \u00eatre trait\u00e9 par chirurgie et dont l'\u00e9tat s'est aggrav\u00e9 apr\u00e8s le traitement initial\">\n                                                                    <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/Facebook.svg\" alt=\"Partager sur Facebook\" title=\"Partager sur Facebook\" \/>Facebook\n                                                                <\/a>\n                                                                                                                            <\/div>\n                                                        <\/div>\n                                                                                                            <\/div>\n                                                    <div class=\"story-post-content\">\n                                                        <a href=\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/\">\n                                                            <p class=\"blue-txt\">Une \u00e9tude sur le cabozantinib chez des personnes atteintes d&rsquo;un cancer du rein \u00e0 un stade avanc\u00e9 qui n&rsquo;a pas pu \u00eatre trait\u00e9 par chirurgie et dont l&rsquo;\u00e9tat s&rsquo;est aggrav\u00e9 apr\u00e8s le traitement initial<\/p>\n                                                        <\/a>\n                                                        <p class=\"second-post-para\">Cabometyx\/Cometriq<\/p>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                        <\/div>\n                                        <br>\n                                                                    <div class=\"row story-row\">\n                                            <div class=\"column-1 col-lg-2 col-md-2 col-sm-12\">\n                                                                                                        <div class=\"story-img\">\n                                                                                                                            <a href=\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/lay-language\/une-etude-pour-en-savoir-plus-sur-leffet-des-boosters-ou-bloqueurs-puissants-du-cyp3a4-sur-les-taux-sanguins-de-tazemetostat-epz-6438-chez-les-patients-atteints-dun-cancer-avance\/\">\n                                                                    <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/defaultImg.png\" alt=\"Une \u00e9tude pour en savoir plus sur l'effet des boosters ou bloqueurs puissants du CYP3A4 sur les taux sanguins de tazemetostat (EPZ-6438) chez les patients atteints d'un cancer avanc\u00e9\" title=\"Une \u00e9tude pour en savoir plus sur l'effet des boosters ou bloqueurs puissants du CYP3A4 sur les taux sanguins de tazemetostat (EPZ-6438) chez les patients atteints d'un cancer avanc\u00e9\" >\n                                                                <\/a>\n                                                                                                                    <\/div>\n                                                                                            <\/div>\n                                            <div class=\"column-2 col-lg-10 col-md-10 col-sm-12\">\n                                                <div class=\"story-post\">\n                                                    <div class=\"story-time-div\">\n                                                        <div class=\"story-info-sec\">\n                                                            <button class=\"btn tag-btn\" style=\"background-color:#224a81\">\n                                                                Lymphome folliculaire \/ sarcome \u00e9pith\u00e9lio\u00efde                                                            <\/button>\n                                                            <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/doc.svg\"\n                                                                class=\"radio-img desk-span\" alt=\"Ic\u00f4ne de document\" title=\"Ic\u00f4ne de document\" srcset=\"\" width=\"auto\">\n                                                            <span class=\"desk-span\">&nbsp;&#8211;&nbsp;\n                                                                <span class=\"story-date\">01 mars 2024                                                                    <!-- <span class=\"story-read-time\">1 \u00a0mn de lecture<\/span> -->\n                                                                <\/span>\n                                                                <p class=\"mob-span\">\n                                                                    <span class=\"story-date\">01 mars 2024<\/span>\n                                                                    <!-- <span class=\"story-read-time\"><\/span> -->\n                                                                <\/p>\n                                                        <\/div>\n                                                                                                                <div class=\"story-share-sec visible\">\n                                                            <div class=\"share\" data-title=\" Une \u00e9tude pour en savoir plus sur l&rsquo;effet des boosters ou bloqueurs puissants du CYP3A4 sur les taux sanguins de tazemetostat (EPZ-6438) chez les patients atteints d&rsquo;un cancer avanc\u00e9\">\n                                                                <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/share-icon.svg\"\n                                                                alt=\"Partager sur les r\u00e9seaux sociaux\" title=\"Partager sur les r\u00e9seaux sociaux\" \/>\n                                                            <\/div>\n                                                            <div class=\"share-tray hidden\">\n                                                                                                                                <a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https:\/\/d14saept1n0koz.cloudfront.net\/fr\/lay-language\/une-etude-pour-en-savoir-plus-sur-leffet-des-boosters-ou-bloqueurs-puissants-du-cyp3a4-sur-les-taux-sanguins-de-tazemetostat-epz-6438-chez-les-patients-atteints-dun-cancer-avance\/&#038;title=Une \u00e9tude pour en savoir plus sur l'effet des boosters ou bloqueurs puissants du CYP3A4 sur les taux sanguins de tazemetostat (EPZ-6438) chez les patients atteints d'un cancer avanc\u00e9&#038;media=\">\n                                                                    <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/LinkedIn.svg\" alt=\"Partager sur LinkedIn\" title=\"Partager sur LinkedIn\" \/>LinkedIn\n                                                                <\/a>\n                                                                                                                                <!--<a href=\"\">\n                                                                    <img decoding=\"async\" src=\"\" alt=\"\" title=\"\" \/>Twitter\n                                                                <\/a>-->\n                                                                                                                                <a href=\"https:\/\/www.facebook.com\/sharer.php?u=https:\/\/d14saept1n0koz.cloudfront.net\/fr\/lay-language\/une-etude-pour-en-savoir-plus-sur-leffet-des-boosters-ou-bloqueurs-puissants-du-cyp3a4-sur-les-taux-sanguins-de-tazemetostat-epz-6438-chez-les-patients-atteints-dun-cancer-avance\/&#038;p=Une \u00e9tude pour en savoir plus sur l'effet des boosters ou bloqueurs puissants du CYP3A4 sur les taux sanguins de tazemetostat (EPZ-6438) chez les patients atteints d'un cancer avanc\u00e9\">\n                                                                    <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/Facebook.svg\" alt=\"Partager sur Facebook\" title=\"Partager sur Facebook\" \/>Facebook\n                                                                <\/a>\n                                                                                                                            <\/div>\n                                                        <\/div>\n                                                                                                            <\/div>\n                                                    <div class=\"story-post-content\">\n                                                        <a href=\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/lay-language\/une-etude-pour-en-savoir-plus-sur-leffet-des-boosters-ou-bloqueurs-puissants-du-cyp3a4-sur-les-taux-sanguins-de-tazemetostat-epz-6438-chez-les-patients-atteints-dun-cancer-avance\/\">\n                                                            <p class=\"blue-txt\">Une \u00e9tude pour en savoir plus sur l&rsquo;effet des boosters ou bloqueurs puissants du CYP3A4 sur les taux sanguins de tazemetostat (EPZ-6438) chez les patients atteints d&rsquo;un cancer avanc\u00e9<\/p>\n                                                        <\/a>\n                                                        <p class=\"second-post-para\">Tazverik<\/p>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                        <\/div>\n                                        <br>\n                                                                    <div class=\"row story-row\">\n                                            <div class=\"column-1 col-lg-2 col-md-2 col-sm-12\">\n                                                                                                        <div class=\"story-img\">\n                                                                                                                            <a href=\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/lay-language\/une-etude-pour-en-savoir-plus-sur-ce-qui-arrive-a-elafibranor-dans-le-corps-sa-securite-et-sa-tolerabilite-chez-des-volontaires-japonais-en-bonne-sante-par-rapport-a-des-volontaires-non-asiatiques-en\/\">\n                                                                    <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/08\/24092617\/Image1.png\" alt=\"Une \u00e9tude pour en savoir plus sur ce qui arrive \u00e0 elafibranor dans le corps, sa s\u00e9curit\u00e9 et sa tol\u00e9rabilit\u00e9 chez des volontaires japonais en bonne sant\u00e9 par rapport \u00e0 des volontaires non asiatiques en bonne sant\u00e9\" title=\"Une \u00e9tude pour en savoir plus sur ce qui arrive \u00e0 elafibranor dans le corps, sa s\u00e9curit\u00e9 et sa tol\u00e9rabilit\u00e9 chez des volontaires japonais en bonne sant\u00e9 par rapport \u00e0 des volontaires non asiatiques en bonne sant\u00e9\" >\n                                                                <\/a>\n                                                                                                                    <\/div>\n                                                                                            <\/div>\n                                            <div class=\"column-2 col-lg-10 col-md-10 col-sm-12\">\n                                                <div class=\"story-post\">\n                                                    <div class=\"story-time-div\">\n                                                        <div class=\"story-info-sec\">\n                                                            <button class=\"btn tag-btn\" style=\"background-color:#224a81\">\n                                                                Cholangite biliaire primitive (CBP)                                                            <\/button>\n                                                            <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/doc.svg\"\n                                                                class=\"radio-img desk-span\" alt=\"Ic\u00f4ne de document\" title=\"Ic\u00f4ne de document\" srcset=\"\" width=\"auto\">\n                                                            <span class=\"desk-span\">&nbsp;&#8211;&nbsp;\n                                                                <span class=\"story-date\">01 f\u00e9vrier 2024                                                                    <!-- <span class=\"story-read-time\">1 \u00a0mn de lecture<\/span> -->\n                                                                <\/span>\n                                                                <p class=\"mob-span\">\n                                                                    <span class=\"story-date\">01 f\u00e9vrier 2024<\/span>\n                                                                    <!-- <span class=\"story-read-time\"><\/span> -->\n                                                                <\/p>\n                                                        <\/div>\n                                                                                                                <div class=\"download-icon\">\n                                                            <a href=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/03\/24092612\/LaySummary_Phase_I_Study_of_Elafibranor_in_Healthy_Asian_Volunteers_715537_01_March_2024.pdf\" target=\"_blank\">\n                                                                <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/download.svg\"\n                                                                alt=\"T\u00e9l\u00e9charger\" title=\"T\u00e9l\u00e9charger\" target=\"_blank\">\n                                                            <\/a>\n                                                        <\/div>\n                                                                                                                <div class=\"story-share-sec visible\">\n                                                            <div class=\"share\" data-title=\" Une \u00e9tude pour en savoir plus sur ce qui arrive \u00e0 elafibranor dans le corps, sa s\u00e9curit\u00e9 et sa tol\u00e9rabilit\u00e9 chez des volontaires japonais en bonne sant\u00e9 par rapport \u00e0 des volontaires non asiatiques en bonne sant\u00e9\">\n                                                                <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/share-icon.svg\"\n                                                                alt=\"Partager sur les r\u00e9seaux sociaux\" title=\"Partager sur les r\u00e9seaux sociaux\" \/>\n                                                            <\/div>\n                                                            <div class=\"share-tray hidden\">\n                                                                                                                                <a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https:\/\/d14saept1n0koz.cloudfront.net\/fr\/lay-language\/une-etude-pour-en-savoir-plus-sur-ce-qui-arrive-a-elafibranor-dans-le-corps-sa-securite-et-sa-tolerabilite-chez-des-volontaires-japonais-en-bonne-sante-par-rapport-a-des-volontaires-non-asiatiques-en\/&#038;title=Une \u00e9tude pour en savoir plus sur ce qui arrive \u00e0 elafibranor dans le corps, sa s\u00e9curit\u00e9 et sa tol\u00e9rabilit\u00e9 chez des volontaires japonais en bonne sant\u00e9 par rapport \u00e0 des volontaires non asiatiques en bonne sant\u00e9&#038;media=https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/08\/24092617\/Image1.png\">\n                                                                    <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/LinkedIn.svg\" alt=\"Partager sur LinkedIn\" title=\"Partager sur LinkedIn\" \/>LinkedIn\n                                                                <\/a>\n                                                                                                                                <!--<a href=\"\">\n                                                                    <img decoding=\"async\" src=\"\" alt=\"\" title=\"\" \/>Twitter\n                                                                <\/a>-->\n                                                                                                                                <a href=\"https:\/\/www.facebook.com\/sharer.php?u=https:\/\/d14saept1n0koz.cloudfront.net\/fr\/lay-language\/une-etude-pour-en-savoir-plus-sur-ce-qui-arrive-a-elafibranor-dans-le-corps-sa-securite-et-sa-tolerabilite-chez-des-volontaires-japonais-en-bonne-sante-par-rapport-a-des-volontaires-non-asiatiques-en\/&#038;p=Une \u00e9tude pour en savoir plus sur ce qui arrive \u00e0 elafibranor dans le corps, sa s\u00e9curit\u00e9 et sa tol\u00e9rabilit\u00e9 chez des volontaires japonais en bonne sant\u00e9 par rapport \u00e0 des volontaires non asiatiques en bonne sant\u00e9\">\n                                                                    <img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/Facebook.svg\" alt=\"Partager sur Facebook\" title=\"Partager sur Facebook\" \/>Facebook\n                                                                <\/a>\n                                                                                                                            <\/div>\n                                                        <\/div>\n                                                                                                            <\/div>\n                                                    <div class=\"story-post-content\">\n                                                        <a href=\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/lay-language\/une-etude-pour-en-savoir-plus-sur-ce-qui-arrive-a-elafibranor-dans-le-corps-sa-securite-et-sa-tolerabilite-chez-des-volontaires-japonais-en-bonne-sante-par-rapport-a-des-volontaires-non-asiatiques-en\/\">\n                                                            <p class=\"blue-txt\">Une \u00e9tude pour en savoir plus sur ce qui arrive \u00e0 elafibranor dans le corps, sa s\u00e9curit\u00e9 et sa tol\u00e9rabilit\u00e9 chez des volontaires japonais en bonne sant\u00e9 par rapport \u00e0 des volontaires non asiatiques en bonne sant\u00e9<\/p>\n                                                        <\/a>\n                                                        <p class=\"second-post-para\">Elafibranor<\/p>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                        <\/div>\n                                        <br>\n                                                            <!-- show pagination here -->\n                                                                        <div class=\"media-pagination-sec\">\n                                            <span aria-current=\"page\" class=\"page-numbers current\">1<\/span>\n<a class=\"page-numbers\" href=\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/wp-json\/wp\/v2\/pages\/19995\/page\/2\/\">2<\/a>\n<a class=\"page-numbers\" href=\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/wp-json\/wp\/v2\/pages\/19995\/page\/3\/\">3<\/a>\n<a class=\"next page-numbers\" href=\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/wp-json\/wp\/v2\/pages\/19995\/page\/2\/\"> <\/a>                                        <\/div>\n                                                                <!-- show pagination Ends here -->\n                                                    <\/div>\n                        <!-- Story Listing ends here -->\n                <\/div>\n                <div class=\"column-2  col-xl-3 col-md-4 col-sm-12\"><\/div>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/section>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:25%\">\n    <section class=\"side-panel contacts-card\">\n        <div class=\"container\">\n            <div class=\"side-media-contacts\">\n    <div class=\"media-contacts-head visible\">\n        <h6 class=\"contact-side heading-six\">\n            Contact        <\/h6>\n    <\/div>\n    <div class=\"media-contacts-list\">\n        <div class=\"main-media-contact-list\">\n                               <ul role=\"presentation\">\n                        <li>\n                            <h5 class=\"name-label visible\">Untitled<\/h5>\n                            <p class=\"designation-label\"><\/p>\n                            <p class=\"designation-country hidden\"><\/p>\n                        <\/li>\n                        <li class=\"parent-list\" role=\"presentation\">\n                          <ul role=\"presentation\"> \n                            \n                            \n                              \n\n                            \n                                                      <\/ul>          \n                        <\/li>\n                                            <\/ul>\n\n                    <hr class=\"down-divider visible\"> \n                                   <ul role=\"presentation\">\n                        <li>\n                            <h5 class=\"name-label visible\">Informations produits\/m\u00e9dicales<\/h5>\n                            <p class=\"designation-label\"><\/p>\n                            <p class=\"designation-country visible\"><\/p>\n                        <\/li>\n                        <li class=\"parent-list\" role=\"presentation\">\n                          <ul role=\"presentation\"> \n                            \n                                                            <li>\n                                    <ul class=\"phone-child visible\" >\n                                        <li class=\"phone\"><img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/Phone-Icon-New.svg\" alt=\"Num\u00e9ro de t\u00e9l\u00e9phone\"><\/li>\n                                        <li class=\"phone-number\" role=\"listitem\" aria-label=\"phone number\" ><a href=\"tel:+33 1 58 33 50 00\" id=\"user_phone\">+33 1 58 33 50 00<\/a><\/li>\n                                        <li class=\"copy-icon\" role=\"listitem\" aria-label=\"copy phone number\" tabindex=\"0\"><img decoding=\"async\" class=\"desktop-view\" data-value=\"+33 1 58 33 50 00\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/Copy-Icon-New.svg\" alt=\"Copier le num\u00e9ro de t\u00e9l\u00e9phone\" title=\"Copier le num\u00e9ro de t\u00e9l\u00e9phone\" ><\/li>\n                                    <\/ul>\n                                <\/li>\n                            \n                              \n\n                                                            <li role=\"presentation\">\n                                    <ul role=\"list\" aria-label=\"email details\" class=\"email-child visible\">\n                                        <li class=\"email\" role=\"listitem\" aria-label=\"email icon\" tabindex=\"0\"><img decoding=\"async\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/Mail-Icon-New.svg\" alt=\"Adresse e-mail\" title=\"Adresse e-mail\"><\/li>\n                                        <li class=\"email-id\" role=\"listitem\" aria-label=\"email id\"><a href=\"mailto:Globalmedinfo@ipsen.com\" id=\"user_email\">Globalmedinfo@ipsen.com<\/a><\/li>\n                                        <li class=\"copy-icon\" role=\"listitem\" aria-label=\"copy email id\" tabindex=\"0\"><img decoding=\"async\" class=\"desktop-view\" data-value=\"Globalmedinfo@ipsen.com\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/Copy-Icon-New.svg\" alt=\"Copier l'adresse e-mail\" title=\"Copier l'adresse e-mail\"><\/li>\n                                    <\/ul>\n                                <\/li>\n                            \n                                                      <\/ul>          \n                        <\/li>\n                                                    <li role=\"presentation\" class=\"mobile-view\">\n                                <a href=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/05\/23132441\/Informations-produitsmedicales.vcf\" class=\"mobile-only add-to-contacts\">\n                                    <img decoding=\"async\" class=\"mobile-only add-contacts\" src=\"https:\/\/d14saept1n0koz.cloudfront.net\/wp-content\/themes\/ipsen-main\/dist\/images\/add-to-contacts.png\" title=\"Ajouter aux contacts\" alt=\"Ajouter aux contacts\" >\n                                <\/a>\n                            <\/li>\n                                            <\/ul>\n\n                    <hr class=\"down-divider visible\"> \n                                 \n        <\/div>\n\n        \n    <\/div>\n<\/div>        <\/div> \n    <\/section>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":225,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-19995","page","type-page","status-publish","hentry","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>R\u00e9sum\u00e9s vulgaris\u00e9s de nos essais cliniques - Global<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"R\u00e9sum\u00e9s vulgaris\u00e9s de nos essais cliniques - Global\" \/>\n<meta property=\"og:url\" content=\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/patients\/resumes-vulgarises-de-nos-essais-cliniques\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-08T09:20:42+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/patients\/resumes-vulgarises-de-nos-essais-cliniques\/\",\"url\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/patients\/resumes-vulgarises-de-nos-essais-cliniques\/\",\"name\":\"R\u00e9sum\u00e9s vulgaris\u00e9s de nos essais cliniques - Global\",\"isPartOf\":{\"@id\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/#website\"},\"datePublished\":\"2023-04-27T04:06:01+00:00\",\"dateModified\":\"2025-08-08T09:20:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/patients\/resumes-vulgarises-de-nos-essais-cliniques\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/patients\/resumes-vulgarises-de-nos-essais-cliniques\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/patients\/resumes-vulgarises-de-nos-essais-cliniques\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Patients\",\"item\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/patients\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"R\u00e9sum\u00e9s vulgaris\u00e9s de nos essais cliniques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/#website\",\"url\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07154612\/Ipsen-logo_168x48-New3.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07154612\/Ipsen-logo_168x48-New3.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"R\u00e9sum\u00e9s vulgaris\u00e9s de nos essais cliniques - Global","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"R\u00e9sum\u00e9s vulgaris\u00e9s de nos essais cliniques - Global","og_url":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/patients\/resumes-vulgarises-de-nos-essais-cliniques\/","og_site_name":"Global","article_modified_time":"2025-08-08T09:20:42+00:00","twitter_card":"summary_large_image","twitter_site":"@ipsengroup","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/patients\/resumes-vulgarises-de-nos-essais-cliniques\/","url":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/patients\/resumes-vulgarises-de-nos-essais-cliniques\/","name":"R\u00e9sum\u00e9s vulgaris\u00e9s de nos essais cliniques - Global","isPartOf":{"@id":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/#website"},"datePublished":"2023-04-27T04:06:01+00:00","dateModified":"2025-08-08T09:20:42+00:00","breadcrumb":{"@id":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/patients\/resumes-vulgarises-de-nos-essais-cliniques\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/d14saept1n0koz.cloudfront.net\/fr\/patients\/resumes-vulgarises-de-nos-essais-cliniques\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/patients\/resumes-vulgarises-de-nos-essais-cliniques\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/"},{"@type":"ListItem","position":2,"name":"Patients","item":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/patients\/"},{"@type":"ListItem","position":3,"name":"R\u00e9sum\u00e9s vulgaris\u00e9s de nos essais cliniques"}]},{"@type":"WebSite","@id":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/#website","url":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/#organization","name":"IPSEN","url":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07154612\/Ipsen-logo_168x48-New3.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07154612\/Ipsen-logo_168x48-New3.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]}]}},"_links":{"self":[{"href":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/wp-json\/wp\/v2\/pages\/19995","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/wp-json\/wp\/v2\/comments?post=19995"}],"version-history":[{"count":21,"href":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/wp-json\/wp\/v2\/pages\/19995\/revisions"}],"predecessor-version":[{"id":81747,"href":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/wp-json\/wp\/v2\/pages\/19995\/revisions\/81747"}],"up":[{"embeddable":true,"href":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/wp-json\/wp\/v2\/pages\/225"}],"wp:attachment":[{"href":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/wp-json\/wp\/v2\/media?parent=19995"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}